Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus

Keywords

Medicine, Fenofibrate, Hazard ratio, Internal medicine, Simvastatin

References

• Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.Juan Francisco Mestre Delgado — 2007
• Effects of intensive glucose lowering in type 2 diabetes.Hertzel C Gerstein, Hertzel C. Gerstein, Michael E. Miller — 2008
• Arch Intern Med:住院增加老年人出院后骨折危险王晓燕 — 2009
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial.Rory Collins, Jane Armitage, Sarah Parish — 2003
• Joint Effects of Serum Triglyceride and LDL Cholesterol and HDL Cholesterol Concentrations on Coronary Heart Disease Risk in the Helsinki Heart Study: Implications for TreatmentVesa Manninen, Leena Tenkanen, Pekka Koskinen — 1992
• Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic SyndromeRussell Scott, Richard O’Brien, Greg Fulcher — 2008
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.Helen M. Colhoun, D. J. Betteridge, Paul N. Durrington — 2004
• Diabetes, Other Risk Factors, and 12-Yr Cardiovascular Mortality for Men Screened in the Multiple Risk Factor Intervention TrialJeremiah Stamler, Olga Vaccaro, James D. Neaton — 1993
• Impact of Diabetes on Mortality After the First Myocardial InfarctionHeikki Miettinen, Seppo Lehto, Veikko Salomaa — 1998
• Heart Protection StudyRory Collins, Jane Armitage, Sarah Parish — 2003
• Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23)R. C. Turner, Helen Millns, H. A. W. Neil — 1998
• Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in HumansArthur Bergman, Gail Murphy, Joanne Burke — 2004
• A More Accurate Method To Estimate Glomerular Filtration Rate from Serum Creatinine: A New Prediction EquationAndrew S. Levey, Juan Bosch, Julia B. Lewis — 1999
• The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up.Thomas Almdal, Henrik Scharling, Jan Skov Jensen — 2004
• Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus.Jacques Genest, Jiří Fröhlich, George Steiner — 2004
• Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.Henry N. Ginsberg, Denise E. Bonds, Laura Lovato — 2007
• Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.Peter H. Jones, Michael H. Davidson — 2005
• Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.David C. Goff, Hertzel C. Gerstein, Henry N. Ginsberg — 2007
• Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.William C. Cushman, Richard H. Grimm, Jeffrey A. Cutler — 2007
• Prevention of the angiographic progression of coronary and vein-graft atherosclerosis by gemfibrozil after coronary bypass surgery in men with low levels of HDL cholesterol. Lopid Coronary Angiography Trial (LOCAT) Study Group.M. H. Frick, Mikko Syvänne, Markku S. Nieminen — 1997

Cited by

• The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides: Impact on Global Health Outcomes) trial: to believe or not to believe?Stephen J. Nicholls — 2012
• Paradoxical negative HDL cholesterol response to atorvastatin and simvastatin treatment in Chinese type 2 diabetic patients.Yu‐Hung Chang, Kun-Cheng Lin, Dao‐Ming Chang — 2013
• Therapeutic Potential of Aleglitazar, a New Dual PPAR-α/γ AgonistCarolyn Patricia Lawby — 2010
• Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapiesЕ.Д. Белега, А.А. Рыбаков, Д.Н. Трубников — 2010
• Pharmacokinetics, efficacy and safety of aleglitazar for the treatment of type 2 diabetes with high cardiovascular risk東次郎 柳, 明生 井上, 直人 志波 — 2011
• Metabolic syndrome: nature, therapeutic solutions and optionsMaria Eugenia Recalde de Payan — 2011
• A physician's guide for the management of hypertriglyceridemia: the etiology of hypertriglyceridemia determines treatment strategy.Boudewijn Klop, J. Wouter Jukema, Ton J. Rabelink — 2012
• The Renoprotective Actions of Peroxisome Proliferator-Activated Receptors Agonists in Diabetes正文 竹下, 浩一 高山, 文彦 大久保 — 2012
• Fibrates: therapeutic potential for diabetic nephropathy?Ana Moreira Jorge, D. Corrêa Lamin Cardoso, Cristina Ponte — 2012
• The Effect of Fenofibrate on Lymphocyte Release of Proinflammatory Cytokines and Systemic Inflammation in Simvastatin‐Treated Patients with Atherosclerosis and Early Glucose Metabolism DisturbancesRhonda S. Kaetzel — 2013
• Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reductionEmilio Mitre Fernández — 2012
• Peroxisome Proliferator–Activated Receptor-α Agonism With Fenofibrate Does Not Suppress Inflammatory Responses to Evoked Endotoxemia昌之 永広 — 2012
• Simvastatin and amlodipine induced thrombocytopenia in the same patient: double trouble and a literature reviewRichard B Kent — 2013
• A Clinician's Guide to the ABCs of Cardiovascular Disease Prevention: The Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts InitiativePedro Martín Ruiz — 2013
• Update FettstoffwechselstörungenMaría Concepción Escorial, María Cristina Chueca, Íñigo Loureiro — 2013
• High-density lipoproteins: a consensus statement from the National Lipid Association.恒遠啓示, 奥田喜代司, 中村嘉宏 — 2013
• Paradox of using intensive lowering of blood glucose in diabetics and strategies to overcome it and decrease cardiovascular risksA.W. Sloley, Karl Kolmetz — 2015
• Use of fibrates in the metabolic syndrome: A review.Gil, I García, Andrés C. Ravelo — 2016
• Intensive LDL Reduction Post Acute Coronary Syndromes: A Catalyst for Improved Outcomes.和朗 大野, 由紀 光江, 沙恵子 島 — 2016
• Pathophysiology and treatment of atherosclerosisJon Stobart — 2017

Related papers

• Clinical observation of simvastatin and fenofibrate in the treatment of type 2 diabetes with hyperlipemiaHE You-zuo — 2008
• Lipoprotein particle analysis comparing simvastatin and fenofibrate.Jean‐Marie Bard, H.J. Parra, G. Luc — 1991
• Observation on the Treatment of Mixed Hyperlipidemia with Simvastatin and Fenofibrate TogetherXiong Qiang-zhen — 2010
• New Fixed-Dose Combinations of Fenofibrate/Simvastatin Therapy Significantly Improve the Lipid Profile of High-Risk Patients with Mixed Dyslipidemia Versus Monotherapies.Christelle Foucher, Patrick Aubonnet, Petr Reichert — 2015
• [The efficacy and tolerance of simvastatin and fenofibrate in primary hypercholesterolemia].J Fricker, P Douste‐Blazy, Pierre Drouin — 1990
• Iatrogenic Severe Depression of High‐Density Lipoprotein CholesterolDavid Mymin, Thomas C. Dembinski, M. H. Friesen — 2009
• Rotavirus vax averts illness in Latin American infants&NA; — 2008
• Effects of simvastatin and fenofibrate on the expression of apolipoprotein MZhao Shui-pin — 2010
• Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patientsGiuseppe Derosa, Pamela Maffioli, Sibilla Salvadeo — 2009
• Effects and mechanism of simvastatin and fenofibrate on the expression of hepatic apolipoprotein M in miceLiu Yang — 2010